Injection site reactions after subcutaneous oligonucleotide therapy

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 340-351

  van Meer, Leonie ^a   Moerland, Matthijs ^a   Gallagher, Jolie ^a   van Doorn, Martijn B A ^b   Prens, Errol P ^b   Cohen, Adam F ^a   Rissmann, Robert ^a   Burggraaf, Jacobus ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

antisense; injection site reaction; oligonucleotide; subcutaneous

Indexed keywords

AGATOLIMOD; ALICAFORSEN; ATL 03; ATL 1102; CPG 10101; DRISAPERSEN; HYB 2055; IMO 3100; IMO 8400; ISIS 104838; ISIS 113715; ISIS 14803; ISIS 325568; ISIS 416858; MIPOMERSEN; MIRAVIRSEN; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; VOLANESORSEN;

CLINICAL FEATURE; DISEASE SEVERITY; DRUG TARGETING; HUMAN; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE NECROSIS; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE ULCER; OLIGONUCLEOTIDE THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 84978732978     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12961     Document Type: Review

References (103)

1. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002; 1: 347–55.
2. Krieg AM. From A to Z on CpG. Trends Immunol 2002; 23: 64–5.
3. Marquis JK, Grindel JM. Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther 2000; 2: 258–63.
4. Monteith DK, Levin AA. Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol Pathol 1999; 27: 8–13.
5. Cavagnaro JA, Levin AA, Henry SP. Toxicology of oligonucleotide therapeutics and understanding the relevance of toxicities. In: Preclinical Safety Evaluation of Biopharmaceuticals: A Science-based Approach to Facilitating Clinical Trials, ed Cavagnaro JA. Hoboken, NJ: Wiley, 2008; 538–74.
6. Crooke ST, Scott H, Kim TW, Kramer-Stickland K, Zanardi T, Fey RA, et al. Toxicologic properties of 2'-methoxyethyl chimeric antisense inhibitors in animals and man. In: Antisense Drug Technology: Principles, Strategies and Applications, ed Crooke ST. Boca Raton, FL: CRC Press, 2008; 327–63.
7. Mipomersen FDA Briefing Document NDA 203568. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, 18 October 2012.
8. Genzyme Corporation. KYNAMRO: Highlights of prescribing information. Cambridge, MA: Genzyme Corporation, 2013.
9. Reuters T. Integrity. Available at: http://thomsonreuters.com/en/products-services/pharma-life-sciences/pharmaceutical-research/integrity.html (last accessed 18 February 2015).
10. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729–35.
11. Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 72–7.
12. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001; 120: 1339–46.
13. van Dongen MGJ, Geerts BF, Morgan ES, Brandt TA, de Kam ML, Romijn JA, et al. First proof of pharmacology in humans of a novel glucagon receptor antisense drug. J Clin Pharmacol 2015; 55: 298–306.
14. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 356: 1728–33.
15. McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ, et al. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol 2006; 44: 88–96.
16. Veedu RN, Wengel J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem Biodivers 2010; 7: 536–42.
17. Seth PP, Jazayeri A, Yu J, Allerson CR, Bhat B, Swayze EE. Structure activity relationships of alpha-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals. Mol Ther Nucleic Acids 2012; 1: e47.
18. Winkler J. Oligonucleotide conjugates for therapeutic applications. Ther Deliv 2013; 4: 791–809.
19. Gish RG, Yuen MF, Chan HL, Given BD, Lai CL, Locarnini SA, et al. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res 2015; 121: 97–108.
20. Vaillant A, Bazinet M. Oligonucleotide chelate complexes. International Patent Application No. PCT/CA2011/000956, 2012.
21. Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 2013; 121: 136–47.
22. van Putten M, Young C, van den Berg S, Pronk A, Hulsker M, Karnaoukh TG, et al. Preclinical studies on intestinal administration of antisense oligonucleotides as a model for oral delivery for treatment of duchenne muscular dystrophy. Mol Ther Nucleic Acids 2014; 3: e211.
23. Haas T, Metzger J, Schmitz F, Heit A, Muller T, Latz E, et al. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 2008; 28: 315–23.
24. Yasuda K, Rutz M, Schlatter B, Metzger J, Luppa PB, Schmitz F, et al. CpG motif-independent activation of TLR9 upon endosomal translocation of ‘natural’ phosphodiester DNA. Eur J Immunol 2006; 36: 431–6.
25. Greaves P. Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation. London: Academic Press, 2012.
26. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4: 211–22.
27. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683–93.
28. Thyssen JP, Maibach HI. Drug-elicited systemic allergic (contact) dermatitis – update and possible pathomechanisms. Contact Dermatitis 2008; 59: 195–202.
29. Ramdial PK, Naidoo DK. Drug-induced cutaneous pathology. J Clin Pathol 2009; 62: 493–504.
30. Weng DE, Masci PA, Radka SF, Jackson TE, Weiss PA, Ganapathi R, et al. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol Cancer Ther 2005; 4: 948–55.
31. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol 2010; 3: 20–31.
32. Taylor S, Grimes P, Lim J, Im S, Lui H. Postinflammatory hyperpigmentation. J Cutan Med Surg 2009; 13: 183–91.
33. Hajishengallis G, Lambris JD. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol 2010; 31: 154–63.
34. Bauer S, Hartmann G. Toll-Like Receptors (TLRs) and Innate Immunity. Berlin: Springer Verlag, 2004.
35. Senn JJ, Burel S, Henry SP. Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther 2005; 314: 972–9.
36. Agrawal S, Kandimalla ER. Role of Toll-like receptors in antisense and siRNA [corrected]. Nat Biotechnol 2004; 22: 1533–7.
37. Richardt-Pargmann D, Vollmer J. Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors. Ann N Y Acad Sci 2009; 1175: 40–54.
38. Burel SA, Han SR, Lee HS, Norris DA, Lee BS, Machemer T, et al. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription three in mice and cynomolgus monkeys. Nucleic Acid Ther 2013; 23: 213–27.
39. Burel SA, Machemer T, Ragone FL, Kato H, Cauntay P, Greenlee S, et al. Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response. J Pharmacol Exp Ther 2012; 342: 150–62.
40. Panelius J, Meri S. Complement system in dermatological diseases – fire under the skin. Front Med (Lausanne) 2015; 2: 3.
41. Dauchel H, Joly P, Delpech A, Thomine E, Sauger F, Le Loet X, et al. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers. Clin Exp Immunol 1993; 92: 274–83.
42. Barreiro LB, Marioni JC, Blekhman R, Stephens M, Gilad Y. Functional comparison of innate immune signaling pathways in primates. PLoS Genet 2010; 6: e1001249.
43. Henry S, Kim TW, Kramer-Stickland K, Zanardi TA, Fey RA, Levin AA. Toxicologic properties of 20-methoxyethyl chimeric antisense inhibitors in animals and man. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd edn, ed Crooke ST. Boca Raton, FL: CRC Press, 2008; 327–63.
44. Kwoh JT. An overview of the clinical safety experience of first- and second-generation antisense oligonucleotides. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd edn, ed Crooke ST. Boca Raton, FL: CRC Press, 2008; 365–99.
45. Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W, et al. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists. Cell Immunol 2011; 270: 126–34.
46. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF, et al. Immune stimulation – a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 1997; 12: 421–32.
47. Ravindran C, Cheng YC, Liang SM. CpG-ODNs induces up-regulated expression of chemokine CCL9 in mouse macrophages and microglia. Cell Immunol 2010; 260: 113–8.
48. Engelhardt JA. Predictivity of animal studies for human injection site reactions with parenteral drug products. Exp Toxicol Pathol 2008; 60: 323–7.
49. Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997; 281: 810–6.
50. Choi SS, Chung E, Jung YJ. Newly identified CpG ODNs, M5-30 and M6-395, stimulate mouse immune cells to secrete TNF-alpha and enhance Th1-mediated immunity. J Microbiol 2010; 48: 512–7.
51. Farman CA, Kornbrust DJ. Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicol Pathol 2003; 31 (Suppl): 119–22.
52. Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, Mortari A, et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2002; 2: 1657–66.
53. Alexander NJ, Clarkson TB, Fulgham DL. Circulating immune complexes in cynomolgus macaques. Lab Anim Sci 1985; 35: 465–8.
54. Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987; 16: 772–8.
55. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA. Phase I trial of ISIS 104838, a 2´-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 2002; 303: 1334–43.
56. Flaim JD, Grundy JS, Baker BF, McGowan MP, Kastelein JJ. Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J Am Heart Assoc 2014; 3: e000560.
57. Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJP, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010; 51: 1057–62.
58. Selvey S, Raal FJ. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces LDL-C in HoFH pediatric patients. J Clin Lipidol 2014; 8: 330.
59. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998–1006.
60. Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 2015; 36: 566–75.
61. Akdim F, Tribble DL, Flaim JD, Yu R, Su J, Geary RS, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011; 32: 2650–9.
62. Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010; 105: 1413–9.
63. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010; 55: 1611–8.
64. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013; 62: 2178–84.
65. Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M. Safety and efficacy of mipomersen administered as add-on therapy in patients with hypercholesterolemia and high cardiovascular risk. J Clin Lipidol 2012; 6: 291–2.
66. Cromwell WC, Santos RD, Blom DJ, Marais DA, Lachmann RH, Gaudet D, et al. Mipomersen, a first-in-class apolipoprotein B synthesis inhibitor, lowers lipoprotein (a) in patients with homozygous familial hypercholesterolemia. J Clin Lipidol 2010; 4: 221.
67. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012; 126: 2283–92.
68. Tardif J-C, Ceska R, Burgess L, Soran H, Gouni-Berthold I, Wagener G, et al. Apolipoprotein B synthesis inhibition by mipomersen reduces LDL-C when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia. J Clin Lipidol 2011; 5: 219–20.
69. Duell PB, Rose JE, Selvey S, Alam S, Mittleman R. Long term efficacy and safety of mipomersen during 4 years of treatment in a cohort of patients with heterozygous familial hypercholesterolemia and coronary artery disease (CAD). J Clin Lipidol 2013; 7: 276.
70. Tsimikas S, Witztum J, Catapano A. Effect of mipomersen on lipoprotein (A) in patients with hypercholesterolemia across four phase III studies. J Am Coll Cardiol 2012; 59: E1494.
71. Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UHW, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012; 33: 1142–9.
72. Patel N, Hegele RA. Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert Opin Pharmacother 2010; 11: 2569–72.
73. McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012; 7: 1–10.
74. Goemans NM, Tulinius M, Van Den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. New Engl J Med 2011; 364: 1513–22.
75. Goemans N, Voit T, McDonald C, Watson C, Kraus J, Rolfe K, et al. Drisapersen treatment for Duchenne muscular dystrophy: results of a 96-week follow-up of an open-label extension study following two placebo-controlled trials. Neurology 2014; 83: e34–40.
76. Flanigan KM, Voit T, Rosales XQ, Servais L, Kraus JE, Wardell C, et al. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Neuromuscul Disord 2014; 24: 16–24.
77. Goemans N, Tulinius M, Wilson R, Wardell C, Bedwell P, Campion G. G.P.113: Drisapersen (DRIS) treatment for Duchenne muscular dystrophy (DMD): results of up to 188 weeksGÇÖ follow-up of an open-label extension study. Neuromuscul Disord 2014; 24: 829.
78. Van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. New Engl J Med 2007; 357: 2677–86.
79. Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014; 13: 987–96.
80. Switaj T, Lasek W. Technology evaluation: HYB-2055, Hybridon. Curr Opin Mol Ther 2005; 7: 376–83.
81. Hwang JJ, Park A, Amin A, Martin RR, Sullivan T, Burns T, et al. A phase I study of HYB2055 in patients (pts) with advanced solid malignancies. J Clin Oncol 2004; 22: 3111.
82. Idera Pharmaceuticals, Inc. Idera Pharmaceuticals Presents Phase 1 Clinical Data for IMO-3100, Lead Candidate for the Treatment of Autoimmune Diseases, and Provides Program Update, 21 October 2010.
83. Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010; 63: 975–83.
84. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004; 27: 460–71.
85. Pashenkov M, Goess G, Wagner C, Hormann M, Jandl T, Moser A, et al. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24: 5716–24.
86. Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009; 7: E58–65.
87. Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 211–7.
88. McHutchison JG, Bacon BR, Gordon SC, Afdhal NH, Jacobson IM, Muir A, et al. Human pharmacologic activity of a new TLR9 agonist antiviral, CPG 10101 (ACTILON). Hepatology 2004; 40: 697A.
89. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007; 46: 1341–9.
90. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther 2007; 12: 741–51.
91. Balak DMW, van Doorn MBA, Rissmann R, Sullivan T, Burggraaf J, Arbeit RD. Results from a randomized, double-blind, placebo-controlled, monotherapy trial of IMO-8400 demonstrate clinical proof-of-concept for Toll-like receptor 7, 8 and 9 antagonism in psoriasis. AAD 2015 Poster 1805. San Francisco, CA: American Academy of Dermatology.
92. Graham MJ, Lee RG, Bell TA, Fu W, Mullick AE, Alexander VJ, et al. Antisense oligonucleotide inhibition of apolipoprotein c-iii reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013; 112: 1479–90.
93. Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014; 371: 2200–6.
94. Liu Q, Bethune C, Dessouki E, Grundy J, Monia BP, Bhanot S. ISIS-FXIRx, a novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers. Blood 2011; Conference: 53rd Annual Meeting of the American Society of Hematology: 18 Nov 2011.
95. Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372: 232–40.
96. Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology 2014; 83: 1780–8.
97. Reesink HW, Janssen HLA, Zeuzem S, Lawitz E, Rodriguez-Torres M, Patel K, et al. Final results-randomized, double-blind, placebo-controlled safety, anti-viral proof-of-concept study of miravirsen, an oligonucleotide targeting MIR-122, in treatment-naive patients with genotype 1 chronic HCV infection. J Hepatol 2012; 56: S26.
98. Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. New Engl J Med 2013; 368: 1685–94.
99. Viney N, Hughes SG, Singleton W, Crooke RM, Graham MJ, Su J, et al. ISIS APO (a) Rx, an antisense inhibitor to apolipoprotein (a), reduces plasma levels of Lp (a) and oxidized phospholipids/apoB-100 in healthy volunteers. Eur Heart J 2014; Conference: European Society of Cardiology: 01 Sep 2014.
100. Geary RS, Bradley JD, Watanabe T, Kwon Y, Wedel M, Van Lier JJ, et al. Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet 2006; 45: 789–801.
101. Brandt TA, Crooke ST, Ackermann EJ, Xia S, Morgan ES, Liu Q, et al. Isis 113715, a novel PTP-1B antisense inhibitor, improves glycemic control and dyslipidemia and increases adiponectin levels in T2DM subjects uncontrolled on stable sulfonylurea therapy. Diabetes 2010; ; Conference: 70th Scientific Sessions of the American Diabetes Association Orlando: 2010.
102. PRNewswire. ATL1103 Phase II Trial – Successful Efficacy Results, 2 September 2014.
103. Isis Pharmaceuticals, Inc. Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX, Press release, 16 June 2014.